Recent News

• 11.04.2026 - Translational Data from Anal Cancer Patients Show Pelareorep Drives HPV-Specific Immune Responses, Supporting its Potential Across HPV-Driven Cancers
• 10.27.2026 - Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers
• 10.20.2026 - Oncolytics Biotech® to Present REO 033 Trial in Progress Abstract at ESMO Showcasing Pelareorep’s Potential in Colorectal Cancer
• 10.14.2026 - Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
• 10.12.2026 - Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
• 09.29.2026 - Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
• 09.28.2026 - Oncolytics Biotech® Reports Accelerating Enrollment in Randomized REO 033 RAS-Mutant, MSS Colorectal Cancer Study
• 09.10.2026 - Oncolytics Biotech® Announces Positive Preclinical Results Combining Pelareorep with a Pan-RAS Inhibitor in Colorectal Cancer
• 08.18.2026 - Oncolytics Biotech® Aligns with FDA on Registrational Path for Second-Line RAS-Mutant MSS Colorectal Cancer
• 07.20.2026 - Oncolytics Biotech® Receives Fast Track Designation for Pelareorep in Second-Line and Later Anal Cancer

Recent Filings

• 11.04.2026 - 8-K Current report
• 11.04.2026 - EX-99.1 EX-99.1
• 10.27.2026 - 8-K Current report
• 10.27.2026 - EX-99.1 EX-99.1
• 10.20.2026 - 8-K Current report
• 10.20.2026 - EX-99.1 EX-99.1
• 10.14.2026 - 8-K Current report
• 10.14.2026 - EX-99.1 EX-99.1
• 10.13.2026 - 8-K Current report
• 10.13.2026 - EX-99.1 EX-99.1